NIPH
BMRN icon

NN Investment Partners Holdings’s BioMarin Pharmaceuticals BMRN Stock Holding History

NN Investment Partners Holdings’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$3M Sell
38,966
-607
-2% -$50.8K 0.02% 492
2021
Q4 		$3.5M Sell
39,573
-59,220
-60% -$4.89M 0.02% 472
2021
Q3 		$7.64M Buy
98,793
+62,105
+169% +$4.9M 0.04% 330
2021
Q2 		$3.06M Buy
36,688
+1,064
+3% +$84.3K 0.02% 495
2021
Q1 		$2.69M Buy
35,624
+659
+2% +$53.8K 0.02% 503
2020
Q4 		$3.07M Buy
34,965
+9,203
+36% +$730K 0.02% 458
2020
Q3 		$1.96M Sell
25,762
-6,274
-20% -$635K 0.01% 491
2020
Q2 		$3.95M Buy
32,036
+4,189
+15% +$416K 0.03% 387
2020
Q1 		$2.35M Buy
27,847
+2,720
+11% +$234K 0.02% 428
2019
Q4 		$2.13M Sell
25,127
-3,326
-12% -$251K 0.01% 486
2019
Q3 		$1.92M Buy
28,453
+5,416
+24% +$417K 0.02% 474
2019
Q2 		$1.97M Buy
23,037
+3,001
+15% +$257K 0.02% 466
2019
Q1 		$1.78M Sell
20,036
-5,135
-20% -$476K 0.01% 500
2018
Q4 		$2.14M Sell
25,171
-156
-0.6% -$14.8K 0.02% 421
2018
Q3 		$2.46M Buy
25,327
+8,352
+49% +$834K 0.02% 417
2018
Q2 		$1.6M Hold
16,975
– – 0.01% 468
2018
Q1 		$1.38M Hold
16,975
– – 0.01% 500
2017
Q4 		$1.51M Sell
16,975
-8,893
-34% -$773K 0.01% 484
2017
Q3 		$2.41M Buy
25,868
+4,491
+21% +$397K 0.02% 452
2017
Q2 		$1.94M Hold
21,377
– – 0.02% 370
2017
Q1 		$1.88M Buy
21,377
+8,039
+60% +$715K 0.02% 355
2016
Q4 		$1.1M Buy
13,338
+5,009
+60% +$431K 0.01% 451
2016
Q3 		$771K Sell
8,329
-4,756
-36% -$448K 0.01% 533
2016
Q2 		$1.02M Sell
13,085
-3,000
-19% -$255K 0.01% 458
2016
Q1 		$1.33M Buy
+16,085
New +$1.31M 0.01% 413

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

NN Investment Partners Holdings's BMRN Position: Q1 2022 in Review

NN Investment Partners Holdings reduced its BioMarin Pharmaceuticals (BMRN) stake by 1.5% in Q1 2022, selling an estimated $50.8K and leaving 38,966 shares worth $3M. The position accounts for 0.02% of the portfolio, ranked #492.

NN Investment Partners Holdings first reported a position in BMRN in Q1 2016 and has held it in 25 quarters since. The position peaked at $7.64M in Q3 2021. 561 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

  • NN Investment Partners Holdings held 38,966 shares of BioMarin Pharmaceuticals worth $3M as of Q1 2022.
  • NN Investment Partners Holdings sold 607 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $50.8K.
  • BioMarin Pharmaceuticals made up 0.02% of NN Investment Partners Holdings's portfolio in Q1 2022, its #492 holding.
  • NN Investment Partners Holdings first reported a position in BioMarin Pharmaceuticals in Q1 2016 and has held it in 25 quarters since.
  • NN Investment Partners Holdings's BioMarin Pharmaceuticals position peaked at $7.64M in Q3 2021.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on NN Investment Partners Holdings's 13F filing for Q1 2022, filed 11 May 2022.